HER2-neu positivity in patients with small and node-negative breast cancer (pT1a,b,N0,M0): A high risk group?

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 9, 2009, Pages 591-598

  Chavez MacGregor, Mariana ^a   Gonzalez Angulo, Ana Maria ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast cancer; HER2; Node negative; Small tumors; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RESEARCH; CANCER STAGING; DISEASE FREE SURVIVAL; DISTANT METASTASIS; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MEDICAL LITERATURE; MEDLINE; OVERALL SURVIVAL; PATIENT SELECTION; PROGNOSIS; RECURRENCE RISK; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM STAGING; RECEPTOR, ERBB-2;

EID: 70349694230     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2008. CA Cancer J Clin. 2008;58:71-96.
2. Fracheboud J, Otto SJ, van Dijck JA, et al. Decreased rates of advanced breast cancer due to mammography screening in The Netherlands. Br J Cancer. 2004;91:861-867.
3. Vacek PM, Geller BM, Weaver DL, et al. Increased mammography use and its impact on earlier breast cancer detection in Vermont, 1975-1999. Cancer. 2002;94:2160-2168.
4. Singletary SE, Allred C, Ashley P, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 2003;83:803-819.
5. Behavioral Risk Factor Surveillance System Public Use Data 2004, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 2005. Available at http://www.cdc.gov/NCCdphp/tracking.htm.
6. American Cancer Society. Breast Cancer Facts & Figures 2007-008. Atlanta, American Cancer Society, Inc. Available at http://www.cancer.org/downloads/stt/bcff-final.pdf.
7. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004; 101:3-27.
8. Chia SK, Speers CH, Bryce CJ, et al. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol. 2004;22:1630-1637.
9. Rosen PP, Groshen S, Kinne DW, et al. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol. 1993;11:2090-2100.
10. Stierer M, Rosen HR, Weber R, et al. Long term analysis of factors influencing the outcome in carcinoma of the breast smaller than one centimeter. Surg Gynecol Obstet. 1992;175:151-160.
11. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:966-978.
12. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol. 2007;25:4952-4960.
13. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676-3685.
14. Ravdin PM, Chamness GC: The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers-a review. Gene. 1995;159:19-27.
15. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
16. Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421:756-760.
17. Yamauchi H, Stearns V, Hayes DF: When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol. 2001;19:2334-2356.
18. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
19. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353:1659-16072.
20. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353: 1673-1684.
21. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC, T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC, TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. 2008 San Antonio Breast Cancer Conference. Abstract #54
22. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809-820.
23. Viani GA, Afonso SL, Stefano EJ, et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153.
24. Chia S, Norris B, Speers C, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol. 2008;26:5697-5704.
25. Joensuu H, Isola J, Lundin M, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res. 2003;9:923-930.
26. Tovey SM, Brown S, Doughty JC, et al. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer. 2009;100:680-683.
27. Untch M, Gelber RD, Jackisch C, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol. 2008;19:1090-1096.
28. Curigliano G, Viale G, Bagnardi V, et al. Clinical Relevance of her-2 overexpression/amplification in patients with small tumor size (pT1a-b) and node-negative breast cancer. J Clin Oncol. 2009. In press,
29. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for breast cancer patietns with HER2-Positive node negative tumors 1 cm or smaller. J Clin Oncol. 2009. In press.
30. Black D, Younger J, Martei Y, et al. Recurrence risk in T1a-b,node-negative, HER2 positive breast cancer. Breast Cancer Res Treat. 2006;100(suppl 1):Abstr 2037.
31. Rodrigues MJ, Wassermann J, Albiges-Sauvin L, et al. Treatment of node-negative infra-centrimetric HER2+ invasive breast carcinomas: A joint AERIO/REMAGUS study. J Clin Oncol. 2009;27: abstr 517.
32. NCCN: Clinical practice guidelines in oncology. Breast cancer. v.1.2009. Available at http://www.nccn.org/professionals/physician_gls/ f_guidelines.asp.
33. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94:852-854.
34. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 2002;94:855-857.
35. Burstein HJ: The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005;353:1652-1654.
36. Hoff ER, Tubbs RR, Myles JL, et al. HER2/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol. 2002;117:916-921.
37. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60-62.
38. Rasmussen BB, Regan MM, Lykkesfeldt AE, et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 2008;9:23-28.